Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 15/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE2A | O00408 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imazodan SCHEMBL124243 | 0.99 | PDE3B (0.97) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7278112 | 0.84 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9670142 | 0.83 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7287604 | 0.82 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7286021 | 0.82 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10468427 | 0.82 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7318837 | 0.81 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10333751 | 0.80 | PDE3B (0.65) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10353452 | 0.78 | SMN1; SMN2 (0.81) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7287414 | 0.77 | PDE3B (0.63) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023196821-A2 | TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. | 2021-11-25 | — | — | US | claimed |
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2021-06-15 | — | — | US | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
| US-4693996-A | SYNERGISTIC MIXTURE OF IMIDAZOLYL-PHENYL-PYRIDAZINONE AND INDANYL-ADENOSINE | WARNER-LAMBERT COMPANY (US) | 1987-09-15 | — | — | US | claimed |
| US-4584299-A | MIXTURE OF HYPOTENSIVE AND CARDIOTONIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-04-22 | — | — | US | claimed |
| EP-0075436-A1 | Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones | WARNER-LAMBERT COMPANY (US) | 1983-03-30 | — | — | EP | claimed |
| US-4353905-A | CARDIOTONIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1982-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | PDE3B 920/4885PDE3A 1257/4885PDE4A 1027/4885 |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | PDE3B 919/4885PDE3A 1257/4885PDE4A 1009/4885 |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | PDE3B 919/4885PDE3A 1257/4885PDE4A 1009/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885PDE4A 1073/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885PDE4A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.